EU and US could reach trade deal this weekend - Reuters
On Monday, Goldman Sachs reiterated a Neutral rating with a $55.00 price target on Bristol-Myers Squibb Co. (NYSE:BMY), currently trading at $49.23, ahead of the company’s first-quarter 2025 earnings release scheduled for April 24. The firm’s analyst pointed out several challenges that Bristol-Myers is expected to face, including headwinds from the redesign of Medicare Part D and inventory destocking, which have been difficult to quantify. InvestingPro data shows the stock’s RSI suggests oversold conditions, while maintaining an impressive 5.04% dividend yield.
Bristol-Myers is navigating through a period where significant generic competition is affecting its legacy products while it attempts to enhance its growth portfolio. With an InvestingPro Financial Health Score rated as GOOD and strong free cash flow yield, the firm’s focus is on the company’s ability to balance the erosion of legacy products due to loss of exclusivity (LOE) against the growth drivers in its portfolio. Key aspects to watch include commercial performance of growth products, updates on the Opdivo Qvantig ramp, and progress in the pipeline.
Additionally, investors are anticipating insights into the company’s capital expenditure priorities, especially in light of the tariff theme and Bristol-Myers’ emphasis on cost management and expense reduction. The company’s stock recently experienced a drop of approximately 3% following the announcement that the Phase 3 label expansion trial for Camzyos did not meet its primary endpoint, despite the trial’s minimal impact on financial projections.
The company’s upcoming Phase 3 ARISE trial result for Cobenfy in the adjunctive schizophrenia setting is now a focal point for investors. According to Goldman Sachs, a positive outcome could lead to around a 2% upside for the stock, with potential for larger sentiment-driven movements depending on the trial’s results.
In other recent news, Bristol-Myers Squibb disclosed that its Phase 3 ODYSSEY-HCM trial for Camzyos, aimed at treating non-obstructive hypertrophic cardiomyopathy (nHCM), did not meet its primary endpoints. Despite the setback, the trial did not reveal any new safety issues. Analysts from BMO Capital Markets and Citi maintained their ratings on the company, with BMO keeping a Market Perform rating and a $61 price target, while Citi held a Neutral rating with a $55 price target. UBS adjusted its price target for Bristol-Myers Squibb to $54 from $60, citing potential impacts from changes in Medicare Part D and upcoming inventory reductions. Goldman Sachs also downgraded the stock from Buy to Neutral, lowering the price target to $55 due to concerns over upcoming patent expirations. The company is facing challenges with patent cliffs but is focusing on cost-cutting and new growth initiatives. Analysts are closely watching the company’s strategic efforts to navigate these issues and the impact on its revenue streams. The developments have led to a reevaluation of treatment approaches for nHCM and the company’s growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.